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HealJh care in the Indian subcontinent had been traditional-
ly blsed on indigenous systems of medicine, especially 
Ayur~eda, Siddha, and Unani, involves herbomineral reme-
di'es. The Western or allopathic system relying mainly on sin-
gle cHemical entities took roots in the country in the earlier 
part 6f the 20th century. Although an indigenous pharma-
ceutisal company was started in 1901, the industry was 
. domi?ated for quite some time by multinational companies 
(MN~s). These MNCs started slowly at first, but later the 
moveinent came close to an avalanche. This. was largely due 
to thJ restrictive Indian Patent Act of 1970, which denied 
prodJct protection to drugs and afforded only protection of 
procekses and that too for a limited period of 7 years from 
the dlte of filing or 5 years from the date of s-ealing. This dis-
. couraked innovative MNCs from filing patents on original 
resea~ch products in India. 
S,imultaneously, the esta blishment of several universi-
ties, technological institutions, and national laboratories in 
India lushered in a formidable technological competence to 
fe-engineer chemical products. This enabled enterprising 
Indiarl companies to synthesize contemporary drugs patent-
ed els~where by the innovators, formulate and market them 
withirl the country competitively and very often before the 
innov~tor MNC could introduce it. Quite often these Indian-
design1ed processes featured novel chemistry and hence led 
to pr6cess patents. This factor - as well as the Indian 
Goverpment's Drug Price Control regulations on selected 
essential medicines - resulted in the country enjoying one of 
the lo~vest prices for drugs in the world. 
59 from a small beginning, the Indian pharmaceutical 
industry's turnover in 1997-1998 was about Rs.120 billion 
or USE> 3 billion. While the value works out to be about 1% 
of the :\Vorld turnover, probably it may be as high as 9% in 
terms lof volume, considering the low prices of drugs in 
India. ~he country is practically self-sufficient in respect of 
most synthetic drugs. 
W,hile ·the Indian pharmaceutical industry made tremen-
dous sltrides, especially in the last two decades, with the 
requir~d capital investments in plants to pr~duce drugs and 
their formulations, significantly there has been no equivalent 
concer& for new drug development in India. Historically the 
reason, have been the high costs involved, lack of interest 
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among innovative MNCs to establish yet another research 
center in India, especially in a hostile patent climate after 
1970, the relatively low turnover of national pharmaceutical 
companies and lack of a vibrant research culture in the 
industry. 
However, after January 1995 - when India signed 
GATT and agreed to respect TRIPS and to amend its patent 
laws on drugs to ·align them with those of the West - the sit-
uation has changed dramatically. MNC discoveries will get 
full product protection for up to 20 years from January 
1995. Assuming a 10-year development period from that 
day to time of registration - from 2005 onward - such 
new drugs will be out of bounds for others. This has prod-
ded some of the bigger Indian companies to invest seriously 
in new drug development. The Indian government also has 
set aside a modest sum to be administered by the 
Department of Science and Technology to support the efforts 
of private industry in drug discovery in collaborative pro-
jects with public sector institutions. Previously it offered few 
marginal incentives to the industry for original R&D work. 
Set up by Ciba Basel through Ciba India in 1963, Ciba 
Research Centre was the first full-fledged unit in the Indian 
private sector. This was practically self-sufficient with 
respect to various aspects of new drug development. It had a 
multidisciplinary team consisting of synthetic and natural 
product chemists, biologists, toxicologists, a metabolism 
group, a team of clinical investigators, al1d extensive animal 
house facilities. It had programs in the area of cardiovascu-
lar diseases, CNS disorders, diabetes, inflammation, fertility, 
hookworm, amoebiasis, bacterial infections including TB 
and viral diseases like small pox and influenza. Soon Ciba of 
India became Hindustan Ciba Ltd. and later Hindustan Ciba 
Geigy Ltd. After the last merger, the Research Centre nar-
rowed down its priorities to parasitic infections including 
amoebiasis and filariasis, fertility control, and the discovery 
of new anti-tubercular agents. Sarabhai Research Centre, set 
up at Baroda a couple of years later, had a limited engage-
ment in new drug development. 
Launched in 1972, Hoechst Research Centre, Bombay, 
began modestly but soon grew into an equally strong insti-
tution with the requisite multidisciplinary team for new drug 
development. In the earlier years, its emphasis had been on 
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cafdiovascular diseases, metabolic disorders, antiinfectives 
ana rheumatism-related arthritis, and chronic inflammatory 
co~ditions. In recent times, it has laid emphasis on isolation 
of 'new molecules from natural sources such as plants and 
I 
microorganisms. An advanced dereplication technology has 
be~n put in place in order to eliminate known compounds at 
an learly stage and to facilitate the isolation of new active 
co~stituents. Currently, it has evolved into an in vitro target-
oriented screening center for drug discovery while retaining 
its post-discovery developmental setup and expertise. Smith-
Kline and French (SKF) had set up a research center in 
Barlgalore exclusively for screening and culturing soils for 
disdovery of new antibiotics, while Boots had established a 
moderate facility in Bombay to synthesize, screen, and devel-
op drugs mainly for diabetes and amoebiasis. Of the four 
meAtioned above, the research units of Ciba, SKF, and Boots 
hav~ been closed in recent years for various reasons while 
thai of Hoechst has been sold to an Indian _group, the 
Pidmals. 
: A singular exception to the rather dismal downturn in 
the IMNC efforts in India for new drug development is 
Astra, which set up Astra Research Centre in 1986. Recently 
thisl has become a fully owned subsidiary of Astra Bio~hemicals Pvt. Ltd. This well-equipped center has a team 
of lnolecular biologists, molecular biophysicists, bio-
che~ists, and synthetic organic chemists and all requisite 
ancillary facilities including an animal house. The center has 
beed focusing on antituberculosis, broad spectrum antibac-
terial, and antimalarial projects, identifying pathogen-specif-
- - ic m'acromolecular targets and developing robust assays for 
.- highl throughput screening. The enzyme transglycosylase 
involved in the cell-wall biosynthesis of bacteria, two homol-
ogoJs sigma subunits of Mycobacterium tuberculosis and 
the ~nzyme Hypoxanthine-Guanine phosphoribosyl trans-
ferase in the malarial parasite are some of the targets that are 
bein~ successfully used for discovering drugs at this center. 
lAs noted earlier, a number of Indian companies have 
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takeI;J- up the challenge of new drug development to face the 
post~GATT scenario. Dr. Reddy's Research Foundation set 
up by Dr. Reddy's Laboratories and Cheminor Drugs, for 
instahce, was started in 1984 as Standard Research Centre. 
It acquired its present name in 1992 when it moved into an 
ultramodern complex near Hyderabad. Set up at a cost of 
USD:6 million, it has a multidisciplinary scientific team, fer-
mentation facilities, and an adequate animal house. Its dis-
coveiy research program focuses on cancer, diabetes, dys-
lipidJmia, obesity, and bacterial infections. The center 
scree~s both synthetic compounds and those derived from 
natur'al sources and has facilities for combinatorial chem-
istry, i molecular modeling, and drug design. 
Ranbaxy Limited, Delhi has set up a similar large facil-
ity nelar Delhi with the emphasis on cardiovascular diseases, 
antic~ncer, and antiinfectives. Among other research centers 
set up by Indian companies to develop new drugs may be 
-menti~ned those of Cadilla Health Care, Ahmedabad (car-
diovalscular drugs), Dabur, Delhi (anticancers), and 
Wockhardt, Aurangabad, which have invested a few million 
dollats each. Lupin Laboratories, Bhopal and Torrent 
Pharmaceuticals, Ahmedabad are also reported to have high 
investlnents in research. A few companies have a more lim-
ited ehgagement, like Recon, Bangalore (anti-inflammato-
ries) 1nd SPIC Pharma R&D Centre, Maraimalai Nagar, 
I 
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Tamilnadu, (antituberculars). The numbers are likely to 
swell in the coming years. For example, U.S. Vitamins has 
announced the setting up of a biotechnology research center 
near Bombay. 
While many companies have registered their interest in 
new drug development, the expenditure as a percentage of 
turnover is still in the single digits, mostly less than 5% in 
contrast to the MNCs' average figure of 15%. The con-
straint has been 'mainly the comparatively lower profitabili-
ty of the Indian companies engendered by stiff market com-
petition, price controls in certain areas, and fragmentation. 
There is a move now in India as elsewhere in the world for 
consolidation by mergers and acquisitions. Coupled with the 
relatively low turnover of even the most successful compa-
nies (USD 250 million), individual investment in research for 
new drugs turns out to be a small figure in the international 
context. However, given the lower cost of trained manpow-
er in India, this is adequate for discovery research for candi-
date drugs but insufficient for development to international 
standards. Licensing out the leads to MNCs and joint devel-
opment are some of the approaches adopted by at least one 
Indian company to overcome this disadvantage. In this con-
text, many companies like Dr. Reddy's Research Foundation, 
Ranbaxy, Recon, and SPIC have collaborative projects with 
national institutions for new drug discovery with somewhat 
modest funding for the latter by the Indian Government's 
Department of Science and Technology. 
Among institutions engaged in drug development, pride 
of place should be given to Central Drug Research Institute 
belonging to the Council of Scientific and Industrial 
Research of the Indian Government. Inaugurated in ~951, 
the institute is equipped to discover new drugs and develop 
them to the marketing stage. Major areas of interest recent-
ly have been antifertility, cardiovascular, and CNS disorders 
(including memory loss due to aging), filariasis, malaria, 
leishmaniasis, and microbial infections. Expertise includes 
not only development of NCEs but also fermentation, vac-
cines, and diagnostics. The institute also has an extensive 
programme for screening natural products as sources for 
new therapeutic agents. 
Many other institutions in India are engaged in various 
areas of biomedical research but without the total set up 
needed for new drug development. Some of these are: 
• Indian Institute of Chemical Biology, Calcutta, which 
was established in 1935 as the first un-official biomed-
ical research institute in India and taken over by CSIR 
in 1956 (bacterial and parasitic infections, genome 
mapping of \,-: cholerae, live oral vaccine for cholera, 
diagnostic for leishmaniasis, identification of markers 
for diagnosis and prognosis of malignant neuroectoder-
mal tumours, chemistry of bioactive substances). 
• Centre for Cellular and Molecular Biology, Hyderabad 
(basic research in cataract, DNA finger printing, devel-
opment of a salt-inducible expression vector system for 
gene c10ners wishing to express proteins in prokaryotic 
systems). 
• Central Institute of Medicinal and Aromatic Plants, 
Lucknow (mainly devoted to genetic improvement, cul-
tivation, production, and chemical processing of eco-
nomically important medicinal and aromatic plants 
such as Artemisia annual has considerable engagement 
in detection and characterization of new antimicrobial, 
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adeny)ate cyclase) although it could not be registered as a 
positiye inotropic and antihypertensive drug. Recombinant 
erythroopoietin used especially in cancer treatment and renal 
failure therapies has been developed by an Indian company 
. I 
and IS, ready to be marketed. 
Among new chemical entities that hold promise as 
drugs I may be mentioned an insulin sensitizer structurally 
relate4 to troglitazone, which has been licensed out, an ami-
dine22 as an antidiabetic, a semi synthetic camptothecin 
derivative with anti-cancer activity, and an alpha lA urose-
lective' adrenergic blocker derived from lactam chemistry 
for w~ich an IND is to be filed for the treatment of benign 
prostate hyperplasia. Two quinolone anibacterials with 
promising activity are under development. 
Ill! lerIII~ uf areas of engagement, the efforts of privare 
industh will continue to be focused on indications like 
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hypertension, diabetes, inflammation, anti-infectives, and 
cancer. For the moment at least, there is only one solitary 
private laboratory working on resistant malaria and tuber-
culosis. Visceral leishmaniasis (Kalazar) calls for urgent solu-
tion but there are no takers. Obviously, anxiety to earn prof-
its takes precedence over attention to a compelling national 
health need. India has become a leading host for AIDS, but 
no concerted effort is still underway in the private or public 
domain to discover and develop affordable drugs that have 
to be necessarily priced considerably lower than the current-
ly available reverse transcriptase or protease inhibitors. 
What is the prognosis for Indian efforts in new drug 
development? Traditiona,lly organic chemists in India have 
been strong both in synthesis and natural products. 
Additionally, they have to be trained in combinatorial chem-
istry and computer-based drug design. This has to be sup-
ported by high-throughput screening. Apart from a few con-
tributions like a monkey model for petit mal epilepsy and 
adaptation of the human hook-worm to neonatal hamster, 
there have been few contributions from Indian research to 
new biological models for drug development. The future 
may see more of these. Work on recombinant DNA-engi-
neered therapeutic pep tides and oligo nucleotide-based 
drugs is yet to take roots, although there have been some 
recent claims of significant progress like the DNA vaccine 
for hepatitis-B being developed by Sanjay Gandhi Post 
Graduate Institute of Medical Sciences, Lucknow. Small 
molecules will continue to be important in new drug devel-
opment in the foreseeable future. 
Through the efforts of the Indian Government's 
Department of Biotechnology, a concerted attempt has been 
made to impart knowledge in molecular biology with grati-
fying results. Thus, scientists with experience in r-DNA tech-, 
nology and cloning are slowly becoming available. These are 
the kingpins in providing the receptors and enzymes that are 
needed for high-throughput screening. 
What is perhaps the most important outcome of such 
efforts is the Good Laboratory Practice, which requires a 
determined and continuous effort to standardize and docu-
ment chemical and biological experimentation and toxico-
logical studies. Equally important is Good Clinical Practice. 
It is interesting to note in this context that Pfizer and Roche 
have started clinical research centers in India. Indian 
attempts to develop new drugs will be viable only if interna-
tional markets can be accessed. GLP and GCP for the devel-
opmental activities and GMP for the production side are 
important issues to be tackled before the resultant products 
will gain international acceptance. Fortunately, the industry 
is getting ready to address these problem areas and to inte-
grate itself successfully in the global search for new drugs. 
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